TriSalus Q2 revenue $11.4M (+1.7% YoY); maintains FY2026 guidance $54-57M

TriSalus Life Sciences, Inc.

Revenue from TriNav system $11.4M, up 1.7% YoY; gross margin improved to 86.8% from 83.9%.
Operating loss widened to $9.8M from $7.3M YoY on higher sales and marketing spend.
Net loss $9.2M ($0.16 loss per share) vs $9.0M ($0.27 loss per share) in Q2 2025.
Cash and equivalents $46.3M after $46.0M equity offering in Q1; runway sufficient for expansion.
CMS established G-code for reimbursement of pressure-generating catheter in office-based labs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.